- Laquinimod
Chembox new
ImageFile=Laquinimod.svg
ImageSize=200
IUPACName=5-chloro-"N"-ethyl-4-hydroxy-1-methyl-2-oxo-
"N"-phenyl-1,2-dihydroquinoline-3-carboxamide
OtherNames=
Section1= Chembox Identifiers
CASNo=248282-07-7
PubChem=216469
SMILES=CCN(c1ccccc1)C(=O)C3=C(/O)c2c(Cl)cccc2N(C)C/3=O
Section2= Chembox Properties
Formula=C19H17ClN2O3
MolarMass=356.803 g/mol
Appearance=
Density=
MeltingPt=
BoilingPt=
Solubility=
Section3= Chembox Hazards
MainHazards=
FlashPt=
Autoignition=Laquinimod is an experimental
immunomodulator developed byActive Biotech and Teva. It is currently investigated as an oral treatment ofmultiple sclerosis (MS).Laquimod is the successor of Active Biotech's failed experimental immunomodulator
linomide . [cite journal |author=Tan IL, Lycklama à Nijeholt GJ, Polman CH et al |title=Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials |journal=Mult Scler |volume=6 |issue=2 |pages=99–104 |year=2000 |month=April |pmid=10773855]The compound has been investigated in two Phase II trials using successive magnetic resonance scans (MRI). Laquinimod seems to be able to reduce the MS disease activity on MRI.cite journal |author=Comi G, Pulizzi A, Rovaris M, "et al" |title=Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study |journal=Lancet |volume=371 |issue=9630 |pages=2085–92 |year=2008 |month=June |pmid=18572078 |doi=10.1016/S0140-6736(08)60918-6] cite journal |author=Polman C, Barkhof F, Sandberg-Wollheim M et al |title=Treatment with laquinimod reduces development of active MRI lesions in relapsing MS |journal=Neurology |volume=64 |issue=6 |pages=987–91 |year=2005 |month=March |pmid=15781813 |doi=10.1212/01.WNL.0000154520.48391.69] However, the response to a given dose was discrepant between both studies. [cite journal |author=Keegan BM, Weinshenker BG |title=Laquinimod, a new oral drug for multiple sclerosis |journal=Lancet |volume=371 |issue=9630 |pages=2059–60 |year=2008 |month=June |pmid=18572062 |doi=10.1016/S0140-6736(08)60894-6]
The Phase III activities have been starting in 2008
External Links
* [http://clinicaltrials.gov/search/intervention=laquinimod Entries in NIH Study Registry]
References
Wikimedia Foundation. 2010.
